- Coloplast’s 3Q revenue from Emerging Markets: DKK 1.22 billion
- Revenue from Europe: DKK 3.76 billion
- Revenue from other developed markets: DKK 1.91 billion
- Analyst recommendations: 10 buys, 12 holds, 5 sells
A look at Coloplast A/S Smart Scores
Factor | Score | Magnitude |
---|---|---|
Value | 2 | |
Dividend | 3 | |
Growth | 3 | |
Resilience | 2 | |
Momentum | 3 | |
OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Coloplast A/S, a company specializing in healthcare products and services, has received a mixed bag of Smartkarma Smart Scores. With a Value score of 2, the company’s stock is considered fair in terms of its price relative to its fundamentals. Coupled with a Dividend score of 3, investors can expect a moderate level of consistent dividend payouts. In terms of Growth and Momentum, Coloplast A/S has scored a 3, indicating a promising outlook for future expansion and market performance. However, with a Resilience score of 2, the company may face some challenges in weathering economic uncertainties.
Despite some areas of concern, the overall long-term outlook for Coloplast A/S appears moderately positive, as indicated by its Smartkarma Smart Scores. As a developer and provider of a wide range of healthcare products catering to various medical needs, the company maintains a global presence, serving healthcare professionals, dealers, and product users worldwide. With a balanced mix of scores in key categories, Coloplast A/S is poised for potential growth and continued market momentum in the foreseeable future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars